Search

Bradley Cook (Cytophage Technologies) and Alexander Hynes (McMaster University) published a new paper on re-evaluating phage therapy criteria. They examine three commonly applied criteria for excluding phages from therapy: the lack of virul

Navy Medicine Research & Development reports that, over a six-year Congressionally Directed Medical Research Programs (CDMRP) award starting in fiscal year 2019, the Naval Medical Research Command worked with the U.S. Naval Research Laborat

On 4 June 2025 the UK Medicines and Healthcare products Regulatory Agency (MHRA) published the UK's first official guidance to support the safe development and use of phage therapies, covering both combined phage products for common infecti

Report from the WHO Regional Office for Europe and the Global Antimicrobial Resistance Research and Development Hub, published 26 May 2025, on advancing the evidence for using bacteriophages against antimicrobial resistance under a One Heal

Another successful phage therapy clinical trial! Armata Pharmaceuticals and colleagues has announced positive topline results from its Phase 1b/2a trial of AP-SA02 for S. aureus bacteremia.

Chase Morgan (University of California San Diego), Haley Atkins (Loyola University Chicago) and colleagues published a new review on phage therapy for urinary tract infections, showing phage therapy for this indication is promising, but nee

The European Commission’s 2025 call sought multicentre, multinational randomised trials of phage therapies for difficult-to-treat bacterial infections, alone or alongside standard care. The call is closed; its deadline was September 16, 202

Armata Pharmaceuticals reported positive topline results from its randomized, placebo-controlled Phase 1b/2a diSArm trial (n=50) of intravenous multi-phage therapeutic AP-SA02 plus best available antibiotic therapy in complicated Staphyloco

You’re invited to submit an abstract to the inaugural Conference on Bacteriophages: Biology, Dynamics, and Therapeutics, chaired by Graham Hatfull (University of Pittsburgh) and Robert (Chip) Schooley (UCSD). Topics range from phage struct

W. Borges (Yale University) and colleagues published a new abstract on personalized phage therapy for cystic fibrosis, showing an LPS-5 and TIVP-H6 phage cocktail decreased P. aeruginosa biofilm formation and reduced IL-6 secretion for 15 d

You’re invited to submit an abstract to the inaugural Conference on Bacteriophages: Biology, Dynamics, and Therapeutics, chaired by Graham Hatfull (University of Pittsburgh) and Robert (Chip) Schooley (UCSD). Topics range from phage struct

Fernando Gordillo Altamirano (Monash University) and colleagues published a new paper on phage therapy failure mechanisms, showing pre-existing anti-prophage antibodies and bacterial heteroresistance contributed to treatment failure in a pa

Researchers at the Center for Phage Biology and Therapy at Yale report in Nature Medicine on nine adults with cystic fibrosis treated by nebulization with phages selected to kill infecting bacteria and also weaken the survivors, making them

You’re invited to submit an abstract to the inaugural Conference on Bacteriophages: Biology, Dynamics, and Therapeutics, chaired by Graham Hatfull (University of Pittsburgh) and Robert (Chip) Schooley (UCSD). Topics range from phage struct

In Episode 45 of the International Antiviral Society (IAS-USA)’s Going anti-Viral podcast, Dr. Michael Saag speaks with Dr. Graham F. Hatfull (University of Pittsburgh) about Bacteriophages for the Treatment of Antimicrobial-resistant Bacte

Benjamin Chan (Yale University) and colleagues published a new paper on outcomes from the first 9 adult CF compassionate use cases treated with personalized inhaled P. aeruginosa phage therapy at Yale. 5-18 days after phage therapy, they sa

Qeen Biotechnologies (Ottawa-Gatineau, Canada) is hiring a Laboratory Technician to support their growing phage R&D and biomanufacturing operations. Please send your CV to teresa.daoud@qeen-bio.com

You’re invited to submit an abstract to the inaugural Conference on Bacteriophages: Biology, Dynamics, and Therapeutics, chaired by Graham Hatfull (University of Pittsburgh) and Robert (Chip) Schooley (UCSD). Topics range from phage struct

Sabrina Green (KU Leuven) wrote a great perspective piece for Nature Microbiology on communicating the promise of phage therapy, her tips on how best to use social media (when memes? when papers?) to get more people to understand its promis

Jagdev Singh (The Children's Hospital at Westmead) and colleagues published a new paper on safety of bronchoscopic and nebulised phage administration, showing no adverse events and improved lung function in two adolescents with cystic fibro